BackAstellas Pharma Overview

Astellas Pharma Cost of Revenue

Cost of Revenue analysis for ALPMY.

Quarterly Cost of Revenue

$189.93B
↑ 147.12% YoY

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$437.52B
↑ 13.88% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin